% | $
Quotes you view appear here for quick access.


  • dsroyal91 dsroyal91 Feb 15, 2013 9:28 AM Flag

    ISCO a source of Revenue

    The amendments extend ISCO's existing rights in the area of parthenogenesis, and the therapeutic use of parthenogenetically derived stem cells for treating any human diseases. Pursuant to the amended agreements ISCO now has an exclusive world-wide license to ACT's patents and applications covering the uses of parthenogenetically derived stem cells in generating human tissue.

    "We're excited to have extended our portfolio of intellectual property which not only allows us to develop new therapeutic and business opportunities, but also makes the possibility of partnering with big pharma practical," commented Dr. Andrey Semechkin, CEO and Co-Chairman of ISCO.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies